Canaccord Genuity analyst Sumant Kulkarni maintained a Buy rating on Voyager Therapeutics Inc (NASDAQ: VYGR) today and set a price target of $35. The company’s shares opened today at $20.28.
Kulkarni observed:
“We spoke with the company and have no reason to believe the reasons for the change are anything other than those cited in the release. VYGR also believes that its CEO search is on track, and we believe an announcement on a new CEO could come in 2H18.”
According to TipRanks.com, Kulkarni is a 2-star analyst with an average return of 0.9% and a 46.6% success rate. Kulkarni covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, Intra-Cellular Therapies, and Alder Biopharmaceuticals.
Currently, the analyst consensus on Voyager Therapeutics Inc is Strong Buy and the average price target is $35.50, representing a 75.0% upside.
In a report issued on May 20, Cowen & Co. also assigned a Buy rating to the stock.
See today’s analyst top recommended stocks >>
Based on Voyager Therapeutics Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $19.93 million. In comparison, last year the company had a GAAP net loss of $16.65 million.
Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Voyager Therapeutics, Inc. operates as a clinical-stage gene therapy company, which develops life-changing treatments for patients suffering from central nervous system. It focuses in the field of adeno-associated virus gene therapy through innovation and investment in vector optimization and engineering, and dosing techniques, as well as process development and production. The company was founded by Guangping Gao, Mark A. Kay, Krystof Bankiewicz and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.
